NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).

Trial Profile

NEO-RIT - Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced KRAS Wildtype Rectal Cancer (Clinical Stages II and III).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Jan 2016

At a glance

  • Drugs Panitumumab (Primary)
  • Indications Rectal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms NEO-RIT
  • Most Recent Events

    • 12 Jan 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as per ClinicalTrials.gov record.
    • 12 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.
    • 08 Dec 2015 Planned End Date changed from 1 Jun 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top